We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now
Read MoreHide Full Article
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has been consistently delivering impressive results, supported by a few encouraging developments.
This leading musculoskeletal healthcare company has a market cap of $28.2 billion.
In the past three months, the company has outperformed its industry. The stock has rallied 18.6% compared with the industry’s 2.5% rise.
Here we discuss factors that make this Zacks Rank #3 (Hold) company worth holding onto for now.
Short-Term Priorities: Zimmer Biomet is pursuing its short-term priorities to address near-term challenges. The priorities include supply recovery, supply efficiency, quality remediation, product launches and providing customer-centric solutions, among others. It is currently on track to complete its detailed remediation plan on the Warsaw North campus by the end of 2019.
Focus on Emerging Markets: Within emerging market, strength in Asia Pacific and EMEA (Europe, the Middle East and Africa) are driving revenues. In the second quarter, sales generated by Zimmer Biomet in EMEA rose 1.9% year over year at CER. Also, Asia-Pacific registered 4.7% year-over-year growth at CER. Banking on several product launches and strong customer adoption, Zimmer Biomet expects the APAC and EMEA market strength to continue through 2019.
Strong Cash Position: Zimmer Biomet exited second-quarter 2019 with cash and cash equivalents of $403.1 million. Long-term debt at the end of the second quarter totaled $6.72 billion, showing a reduction from $8.81 billion in the first quarter. Year to date, net cash provided by operating activities was $584.6 million.
Downsides
However, there are a few factors which have been impeding growth of late.
Pricing Pressure Persists: Pricing continues to remain a major headwind for Zimmer Biomet. The company’s top-line growth in the reported quarter was partially offset by continued pricing pressure, mostly in the American and European markets. In the second quarter of 2019, pricing pressure was a negative 2.7%, in line with the company's expectations.
Competitive Landscape: The presence of a large number of players has made the medical devices market intensely competitive. The orthopedic industry in particular is highly competitive with the presence of players like Stryker, Johnson & Johnson and Medtronic.
Which Way Are Estimates Treading?
For the third quarter of 2019, the Zacks Consensus Estimate for loss is pegged at $1.76, mirroring 7.98% growth from the year-ago quarter. The same for revenues is pegged at $1.87 billion, calling for year-over-year growth of 1.96%.
For 2019, the Zacks Consensus Estimate for earnings is pegged at $7.82, which suggests a 2.4% year-over-year rise. The same for revenues is pegged at $7.95 billion, which indicates a 0.3% rise from the prior-year quarter.
Haemonetics’ long-term earnings growth rate is expected to be 13.5%.
Medtronic’s long-term earnings growth rate is projected at 7.32%.
Amedisys’ long-term earnings growth rate is expected to be 16.26%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has been consistently delivering impressive results, supported by a few encouraging developments.
This leading musculoskeletal healthcare company has a market cap of $28.2 billion.
In the past three months, the company has outperformed its industry. The stock has rallied 18.6% compared with the industry’s 2.5% rise.
Here we discuss factors that make this Zacks Rank #3 (Hold) company worth holding onto for now.
Short-Term Priorities: Zimmer Biomet is pursuing its short-term priorities to address near-term challenges. The priorities include supply recovery, supply efficiency, quality remediation, product launches and providing customer-centric solutions, among others. It is currently on track to complete its detailed remediation plan on the Warsaw North campus by the end of 2019.
Focus on Emerging Markets: Within emerging market, strength in Asia Pacific and EMEA (Europe, the Middle East and Africa) are driving revenues. In the second quarter, sales generated by Zimmer Biomet in EMEA rose 1.9% year over year at CER. Also, Asia-Pacific registered 4.7% year-over-year growth at CER. Banking on several product launches and strong customer adoption, Zimmer Biomet expects the APAC and EMEA market strength to continue through 2019.
Strong Cash Position: Zimmer Biomet exited second-quarter 2019 with cash and cash equivalents of $403.1 million. Long-term debt at the end of the second quarter totaled $6.72 billion, showing a reduction from $8.81 billion in the first quarter. Year to date, net cash provided by operating activities was $584.6 million.
Downsides
However, there are a few factors which have been impeding growth of late.
Pricing Pressure Persists: Pricing continues to remain a major headwind for Zimmer Biomet. The company’s top-line growth in the reported quarter was partially offset by continued pricing pressure, mostly in the American and European markets. In the second quarter of 2019, pricing pressure was a negative 2.7%, in line with the company's expectations.
Competitive Landscape: The presence of a large number of players has made the medical devices market intensely competitive. The orthopedic industry in particular is highly competitive with the presence of players like Stryker, Johnson & Johnson and Medtronic.
Which Way Are Estimates Treading?
For the third quarter of 2019, the Zacks Consensus Estimate for loss is pegged at $1.76, mirroring 7.98% growth from the year-ago quarter. The same for revenues is pegged at $1.87 billion, calling for year-over-year growth of 1.96%.
For 2019, the Zacks Consensus Estimate for earnings is pegged at $7.82, which suggests a 2.4% year-over-year rise. The same for revenues is pegged at $7.95 billion, which indicates a 0.3% rise from the prior-year quarter.
Key Picks
A few better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Medtronic (MDT - Free Report) and Amedisys (AMED - Free Report) , each carrying a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics’ long-term earnings growth rate is expected to be 13.5%.
Medtronic’s long-term earnings growth rate is projected at 7.32%.
Amedisys’ long-term earnings growth rate is expected to be 16.26%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>